Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CADI-R702
- Development stage
- Preclinical
- Lead developer
- Bio-Modeling Systems
- Modality
- Small Molecules
01
Overview
CADI-R702 is a discovery-stage therapeutic program developed by Bio-Modeling Systems (BMSystems) for applications in dermatology. The program is based on the company's proprietary CADI™ (Computer Assisted Deductive Integration) platform, which utilizes heuristic biological modeling to map complex disease pathways and identify novel therapeutic targets or treatment protocols. As a discovery-phase entry, specific details regarding its molecular target or mechanism of action are currently proprietary, though the CADI approach typically focuses on integrative biology to address multifactorial pathologies by identifying non-obvious therapeutic interventions.
Beyond the preview
Go deeper on CADI-R702.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CADI-R702.